Bernstein upgrades Novo Nordisk to “outperform” on $130 bln obesity drug market

Bernstein upgraded Novo Nordisk to "outperform" from "market perform," setting a new price target of DKK540, representing a 54% upside despite the stock's significant year-to-date underperformance. The upgrade is predicated on the market overlooking Novo's robust obesity treatment pipeline and future catalysts, including an anticipated rebound in Wegovy prescriptions by 2026 following a ban on illegal copycat products, the expected U.S. approval and 2026 launch of oral semaglutide, and promising head-to-head trial results for CagriSema against Eli Lilly's Zepbound in early 2026. These factors, coupled with a reduced reliance on semaglutide and the new CEO's focus on re-energizing launches, are projected to drive 12% annual earnings growth through 2030.

Analysis

Bernstein has upgraded Novo Nordisk to "outperform," presenting a contrarian view on the stock which has underperformed the pharmaceutical sector by approximately 40% year-to-date and fallen 60% from its June 2024 peak. The upgrade is underpinned by a new DKK540 price target, implying a 54% upside from its recent close, despite a reduction from a previous DKK620 target. The core of the bullish thesis rests on three key catalysts that Bernstein believes the market is overlooking. First is a potential 2026 rebound in Wegovy prescriptions, contingent on a U.S. ban of illegal copycat semaglutide products, which could shift a significant portion of their 30% market share to Novo. Second is the pipeline expansion with an oral semaglutide version, anticipated for a 2026 launch with projected sales of $6.4 billion by 2030. Third, and most significant, is the potential for CagriSema to demonstrate superior weight loss in head-to-head trials against Eli Lilly's Zepbound in early 2026, with analysts forecasting it could become a top revenue driver with $11 billion in 2030 sales. These developments are also strategically crucial as they reduce Novo's revenue exposure to semaglutide generics from over 70% a year ago to a more manageable 45%. Despite competitive pressure from Eli Lilly and execution risk under a new CEO, Bernstein projects a 12% annual earnings growth for Novo from 2025 to 2030, exceeding the sector average.

Key Decisions for Investors

• Investors should consider the disconnect between the stock's recent 60% price decline and the long-term catalysts identified by Bernstein, viewing this as a potential entry point ahead of key pipeline and regulatory milestones.
• It is critical to monitor the early 2026 head-to-head trial results for CagriSema versus Eli Lilly's Zepbound, as superiority data would be a significant catalyst for re-rating the stock.
• Monitor regulatory developments regarding the ban of compounded semaglutide in the U.S. and the FDA approval timeline for oral semaglutide by the end of 2025, as these are foundational to the Wegovy rebound and portfolio expansion thesis.
• Assess the new CEO's ability to execute on the re-energized obesity franchise strategy, as successful new product launches are essential to realizing the projected 12% annual earnings growth and defending market share against Eli Lilly.